Wegovy Pill Launch Exceeds Expectations, But Pricing and Competition Risks Loom

What happened

Novo Nordisk's oral Wegovy pill has launched stronger than anticipated, with initial prescription volumes surpassing Wall Street estimates. The company reported Q1 2026 Wegovy pill sales of DKK 2,256 million and weekly TRx tracking showing robust uptake. However, the stock remains under pressure as the market focuses on the sustainability of this demand. The critical test ahead is whether patients will persist after the introductory $149/month pricing steps up to $199/$299. Meanwhile, Eli Lilly has already matched the entry price and launched its own oral GLP-1, Foundayo, intensifying competition. Novo's U.S. net pricing is expected to decline further in 2026 due to rebates and mix shifts, and the Jan 1, 2027 WAC reset to $675 adds longer-term uncertainty. The stock at $43 trades at 10.1x P/E, implying a sharp slowdown that may not fully reflect the potential of oral Wegovy if it retains patients through price increases.

Implication

The positive initial data on Wegovy pill uptake validates the thesis that oral semaglutide can expand the addressable market and offset injectable share losses. However, the stock's cheap valuation already prices in significant headwinds. For the investment to work, oral prescriptions must show persistence through the $199 and $299 price levels over the next 3-6 months, and Novo must stabilize its overall GLP-1 market share against Lilly's aggressive entry. The upcoming Part D obesity pilot and 2027 price reset are additional catalysts but carry execution risk. A disciplined entry near $40 with a stop at a material deterioration in oral TRx remains prudent. The stock is a hold/watch for evidence of persistence; only add if the weekly data shows sustained demand beyond the starter period.

Thesis delta

The news strengthens the bull case that oral Wegovy can drive volume growth, but the core thesis remains unchanged: the stock's fate hinges on persistence through price step-ups and competitive dynamics. The data so far is encouraging but not yet decisive; the market's skepticism remains justified until we see if patients are willing to pay $199+/month. No shift in rating or conviction yet; the watch continues.